3D Systems Announces FDA Clearance for World’s First 3D-Printed PEEK Cranial Implants
15 Aprile 2024 - 2:30PM
Today, 3D Systems (NYSE:DDD) announced the Food and Drug
Administration (FDA) has provided 510(k) clearance for its
3D-printed, patient-specific cranial implant solution — VSP® PEEK
Cranial Implant. VSP PEEK Cranial Implant includes a complete
FDA-cleared workflow comprising segmentation and 3D modeling
software, the 3D Systems EXT 220 MED 3D printer, Evonik VESTAKEEP®
i4 3DF PEEK (polyetheretherketone), and a pre-defined production
process. By utilizing additive manufacturing solutions, this
technology can produce patient-specific cranial implants with up to
85% less material than similar implants produced by traditional
machining, which can lead to significant cost savings for an
expensive raw material like implantable PEEK. Furthermore, the
cleanroom-based architecture of the printer combined with
simplified post-processing workflows makes it an ideal technology
for producing patient-specific medical devices at the hospital site
with faster turnaround while keeping the overall cost under
control. To date, this solution has been used to enable nearly 40
successful cranioplasties in Switzerland at University Hospital
Basel, in Austria at Salzburg University Hospital, and in Israel at
Tel-Aviv Sourasky Medical Center.
“3D-printed PEEK cranial plates are an innovative solution that
can improve patient care and expand the possibilities for precise,
individualized neurosurgery,” said Dr. Johannes Pöppe, senior
attending surgeon, department of neurosurgery, University Hospital
Salzburg. “The solution is revolutionizing the field. The
combination of 3D Systems’ printing technology that is uniquely
engineered for sterile environments along with the mechanical
properties of PEEK are helping surgeons push boundaries. Within our
hospital, we have already completed several successful surgeries
using these technologies. I believe the potential for customized
PEEK cranial plates is significant to integrate 3D printing into
routine clinical practice.”
The VSP PEEK Cranial Implant is the first FDA-cleared,
additively manufactured PEEK implant intended for cranioplasty
procedures to restore defects in the skull. This implant-grade,
high-performance polymer has a well-known clinical history in
medical device applications due to its exceptional performance with
mechanical properties closely mirroring human bone. In addition,
PEEK has excellent biocompatibility, resistance to bodily fluids,
and stability in a wide range of temperatures, making it an ideal
choice for many medical device applications. Furthermore, its
inherent radiolucency ensures minimal interference in medical
imaging, facilitating a clearer evaluation of the surgical site and
implant integrity.
“As a leader in medical device innovation, 3D Systems prides
itself on pioneering advancements that benefit both surgeons and
patients,” said Dr. Gautam Gupta, SVP & general manager,
medical devices, 3D Systems. “Receiving FDA clearance for our VSP
PEEK Cranial Implant solution is a significant milestone in our
journey. Our EXT 220 MED printing system has already enabled the
production of nearly 40 cranial implants in support of successful
cranioplasties throughout Europe. With this FDA clearance, we are
now able to bring VSP PEEK Cranial Implant to the U.S. — setting a
new standard of excellence for these procedures. We are now looking
to the next applications for this technology, which includes
3D-printed spine interbody fusion implants, carbon fiber-reinforced
PEEK for plating applications in trauma and fixation, and
bioresorbable polymers for large bone and craniomaxillofacial
applications.”
3D Systems has worked with surgeons for more than a decade to
plan over 150,000 patient-specific cases and manufacture more than
two million implants and instruments for 100+ CE-marked and
FDA-cleared devices from its world-class, FDA-registered, ISO
13485-certified facilities in Littleton, Colorado and Leuven,
Belgium.
This FDA clearance enables 3D Systems to significantly expand
its PEEK product portfolio through the EXT 220 MED platform. With
this milestone, the company is not just introducing a pioneering
product; it is setting the stage for a comprehensive range of
advanced PEEK-based solutions designed to meet the diverse needs of
the medical field. 3D Systems' extensive experience in developing
patient-specific, high-performance PEEK implants, combined with its
robust database, places the company in an unparalleled position to
accelerate the development process. This expertise is a valuable
asset for all existing customers and partners, offering them an
expedited pathway to bring their products to market. By leveraging
3D Systems' proven track record and the capabilities of the EXT 220
MED platform, the company is committed to supporting its partners
in navigating the regulatory landscape more efficiently, ensuring
faster access to innovative medical solutions that enhance patient
care and outcomes.
It is anticipated that the use of 3D-printed cranial implants
will accelerate based on the availability of advanced technologies.
According to a report by Acumen Research and Consulting in February
2023, the cranial implants market size in 2021 was roughly $1.2
billion and is anticipated to approach $2.1 billion by 2030.
Cranial implants can address a breadth of applications including
trauma, defects, and reconstruction. The continued innovation in
materials and manufacturing methodologies such as 3D printing are
expected to enable new solutions to catalyze growth in this
market.
Forward-Looking StatementsCertain statements
made in this release that are not statements of historical or
current facts are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the company to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. In many cases, forward-looking statements can be
identified by terms such as "believes," "belief," "expects," "may,"
"will," "estimates," "intends," "anticipates" or "plans" or the
negative of these terms or other comparable terminology.
Forward-looking statements are based upon management’s beliefs,
assumptions, and current expectations and may include comments as
to the company’s beliefs and expectations as to future events and
trends affecting its business and are necessarily subject to
uncertainties, many of which are outside the control of the
company. The factors described under the headings "Forward-Looking
Statements" and "Risk Factors" in the company’s periodic filings
with the Securities and Exchange Commission, as well as other
factors, could cause actual results to differ materially from those
reflected or predicted in forward-looking statements. Although
management believes that the expectations reflected in the
forward-looking statements are reasonable, forward-looking
statements are not, and should not be relied upon as a guarantee of
future performance or results, nor will they necessarily prove to
be accurate indications of the times at which such performance or
results will be achieved. The forward-looking statements included
are made only as of the date of the statement. 3D Systems
undertakes no obligation to update or revise any forward-looking
statements made by management or on its behalf, whether as a result
of future developments, subsequent events or circumstances or
otherwise, except as required by law.
About 3D Systems More than 35 years ago, 3D
Systems brought the innovation of 3D printing to the manufacturing
industry. Today, as the leading additive manufacturing solutions
partner, we bring innovation, performance, and reliability to every
interaction - empowering our customers to create products and
business models never before possible. Thanks to our unique
offering of hardware, software, materials, and services, each
application-specific solution is powered by the expertise of our
application engineers who collaborate with customers to transform
how they deliver their products and services. 3D Systems’ solutions
address a variety of advanced applications in healthcare and
industrial markets such as medical and dental, aerospace &
defense, automotive, and durable goods. More information on the
company is available at www.3dsystems.com.
Investor Contact: |
investor.relations@3dsystems.com |
Media Contact: |
press@3dsystems.com |
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/1b0e93f6-7c81-4851-86ba-bea4e246e3ec
Grafico Azioni 3D Systems (NYSE:DDD)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni 3D Systems (NYSE:DDD)
Storico
Da Gen 2024 a Gen 2025